Phio Pharmaceuticals Corp. announced on November 7, 2024, that it would present clinical data from its ongoing Phase 1b clinical trial for PH-762 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8-10, 2024. The presentation highlighted early clinical results from patients enrolled in Cohorts 1 and 2 of the dose escalation trial. Intratumoral injection of PH-762 was well tolerated in all patients enrolled to date.
The company reported no related adverse events, no serious adverse events, and no dose-limiting toxicities or dose adjustments. For two patients in the second cohort, one with cutaneous squamous cell carcinoma achieved a complete response, demonstrating 100% tumor clearance. Another patient with cutaneous squamous cell carcinoma achieved a partial response, showing 90% tumor clearance.
Patients in the first cohort of the study exhibited stable disease. These early clinical results are encouraging, indicating both a favorable safety profile and initial signs of efficacy for PH-762 in treating cutaneous carcinomas. The ongoing Phase 1b trial is designed to evaluate the safety and tolerability of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.